Medical Preventative - CMEducation Resources IQ&A Cardiovascular Intelligence Zone | The Medical and Preventive Cardiologist's Perspective

Skip to main content

Featured Authorities on MEDICAL AND PREVENTIVE Cardiology

Dan Atar, MD

Head of Research
Oslo University Hospital Ulleval
Professor of Cardiology
University of Oslo
Oslo, Norway
Visiting Associate Professorship
Johns Hopkins University
Baltimore, Maryland

Christie M. Ballantyne, MD

Christie M. Ballantyne, MD

Director, Center for Cardiovascular Disease Prevention
Methodist DeBakey Heart Center
Chief of the Section of Cardiovascular Research
Director of Atherosclerosis Laboratory
Professor of Medicine
Baylor College of Medicine
Houston, TX

Michael J. Blaha, MD, MPH

Michael J. Blaha, MD, MPH

Director of Clinical Research
Ciccarone Center for the Prevention of Heart Disease
Associate Professor of Medicine
Johns Hopkins School of Medicine
Baltimore, MD

Michael H. Davidson, MD, FACC, FACP, FNLA

Michael H. Davidson, MD, FACC, FACP, FNLA

Clinical Professor
Director of Preventive Cardiology
The University of Chicago Hospitals and Clinic
Pritzker School of Medicine
Chicago, Illinois

Sergio Fazio, MD

Sergio Fazio, MD

Director, Center for Preventive Cardiology
Professor of Medicine
Division of Cardiovascular Medicine
School of Medicine
Oregon Health Sciences University (OHSU)
Portland, OR

Keith A.A. Fox, MBChB, FRCP, FMedSci

Keith A.A. Fox, MBChB, FRCP, FMedSci

Professor, University of Edinburgh
Department of Cardiovascular Medicine
Professor, University and Royal Infirmary
Edinburgh, United Kingdom

Samuel Z. Goldhaber, MD

Samuel Z. Goldhaber, MD

Professor of Medicine
Harvard Medical School
Interim Chief, Division of Cardiovascular Medicine
Director, Thrombosis Research Group
Cardiovascular Division
Head, Vascular Medicine
Brigham and Women's Hospital
Boston, Massachusetts

Shaun Goodman, MD, MSc, FRCPC, FACC, FESC, FAHA

Shaun Goodman, MD, MSc, FRCPC, FACC, FESC, FAHA

Associate Head, Division of Cardiology
St. Michael’s Hospital
Professor, Department of Medicine
University of Toronto
Toronto, Ontario

J. Wouter Jukema, MD, PhD, FESC, FACC MC

J. Wouter Jukema, MD, PhD, FESC, FACC MC

Professor of Cardiology
Netherlands Heart Foundation
Chairman, Leiden Vascular Medicine
Leiden University Medical Center (LUMC)
Leiden, Netherlands

Stephen J. Nicholls, MD

Stephen J. Nicholls, MD

SAHMRI Deputy Director and Heart Foundation Heart Health Theme Leader
Professor of Cardiology
University of Adelaide
Consultant Cardiologist
Royal Adelaide Hospital
Adelaide, Australia

Paul Ridker, MD

Paul Ridker, MD

Eugene Braunwald Professor
Harvard Medical School
Division of Cardiovascular Medicine
Director, Center for Cardiovascular Disease Prevention
Brigham and Women’s Hospital
Boston, MA

Matthew T. Roe, MD

Matthew T. Roe, MD

Professor of Medicine
Duke Clinical Research Institute
Duke University School of Medicine
Durham, NC

Robert S. Rosenson, MD

Robert S. Rosenson, MD

Professor of Medicine (Cardiology)
Mount Sinai Icahn School of Medicine
Director, Cardiometabolics Unit
Mount Sinai Heart Institute
New York, NY

Christian Ruff, MD

Christian Ruff, MD

Principal Investigator, ENGAGE-AF Trial
TIMI Group
Director, General Cardiology
Brigham and Women’s Hospital
Assistant Professor of Medicine
Harvard Medical School
Boston, MA

Freek W A Verheugt, MD, PhD

Freek W A Verheugt, MD, PhD

Professor of Cardiology
Chairman of the Department of Cardiology
Heartcenter of the University Medical Center
Nijmegen, The Netherlands

R. Scott Wright, MD

R. Scott Wright, MD

Professor of Medicine
Department of Cardiovascular Medicine
Cardiovascular Division
Mayo Clinic

ABOUT THIS PROGRAM
AND FACULTY DISCLOSURES

PCSK9-FOCUSED RESOURCES
and TRIALS

Latest Videos |view all videos

Showing 1 - 12 of 98 results

Previous| 1 | 2 | 3 | 4 | 5 ...9 |Next

You have identified the challenges of accessing PCSK9 inhibitors for patients whose CV risk is genetic vs. those whose clinical course is characterized by progressive vascular events. How do you approach each subset with respect to LDL-C management?

You have identified the challenges of accessing PCSK9 inhibitors for patients whose CV risk is genetic vs. those whose clinical course is characterized by progressive vascular events. How do you approach each subset with respect to LDL-C management?

What have we learned from the ODYSSEY Outcomes pharmacoeconomic analysis that you and Professor Deepak Bhatt reported at the AHA 2018 Meeting? And what are the implications for the clinician-cardiologist who is making the case to payors?

What have we learned from the ODYSSEY Outcomes pharmacoeconomic analysis that you and Professor Deepak Bhatt reported at the AHA 2018 Meeting? And what are the implications for the clinician-cardiologist who is making the case to payors?

With the results of ODYSSEY Outcomes and the more attractive pricing for PCSK9 inhibitors, how do you now see the landscape for this therapy, especially in the context of the lipid medicine/atherosclerosis specialist and the preventive cardiologist?

With the results of ODYSSEY Outcomes and the more attractive pricing for PCSK9 inhibitors, how do you now see the landscape for this therapy, especially in the context of the lipid medicine/atherosclerosis specialist and the preventive cardiologist?

From a safety perspective how do you counsel your patients in whom you are beginning PCSK9 inhibitor therapy?

From a safety perspective how do you counsel your patients in whom you are beginning PCSK9 inhibitor therapy?

As the Director of the Center for Cardiovascular Disease Prevention, what patient types on the risk landscape of ASCVD do you believe deserve special attention because they are likely to be eligible candidates for PCSK9-mediated LDL-C reduction?

As the Director of the Center for Cardiovascular Disease Prevention, what patient types on the risk landscape of ASCVD do you believe deserve special attention because they are likely to be eligible candidates for PCSK9-mediated LDL-C reduction?

Based on ODYSSEY Outcomes, for which biological/metabolic risk markers do you feel that cardiologists and atherosclerosis specialists should strive to achieve LDL-C levels even more aggressive than those identified in the AHA Guidelines?

Based on ODYSSEY Outcomes, for which biological/metabolic risk markers do you feel that cardiologists and atherosclerosis specialists should strive to achieve LDL-C levels even more aggressive than those identified in the AHA Guidelines?

As a leading authority in LDL-C-mediated CV risk reduction, can you provide us with your perspective on the evidence for PCSK9 inhibitors as a foundational approach for managing a broad spectrum of patients with high risk coronary heart disease?

As a leading authority in LDL-C-mediated CV risk reduction, can you provide us with your perspective on the evidence for PCSK9 inhibitors as a foundational approach for managing a broad spectrum of patients with high risk coronary heart disease?

What is the true incidence of statin intolerance and how do you diagnose it? And what is your approach to re-challenge and titration with other statins? And where do alirocumab and evolocumab fit into the statin intolerance treatment plan?

What is the true incidence of statin intolerance and how do you diagnose it? And what is your approach to re-challenge and titration with other statins? And where do alirocumab and evolocumab fit into the statin intolerance treatment plan?

How do you see the future of access, affordability, and general utilization of PCSK9 inhibitors as a result of the price reductions and results from CV outcome trials?

How do you see the future of access, affordability, and general utilization of PCSK9 inhibitors as a result of the price reductions and results from CV outcome trials?

As a program director with a mandate to improve quality of CV care, how do you see role of PCSK9 inhibitors in subspecialty groups—interventional cardiologists, medical/preventive cardiologists, lipidologists/ASCVD, and diabetes specialists?

As a program director with a mandate to improve quality of CV care, how do you see role of PCSK9 inhibitors in subspecialty groups—interventional cardiologists, medical/preventive cardiologists, lipidologists/ASCVD, and diabetes specialists?

How do you recommend that clinicians directly and immediately apply the results of the CV outcome trials with alirocumab and evolocumab directly to the front lines of medical cardiology practice?

How do you recommend that clinicians directly and immediately apply the results of the CV outcome trials with alirocumab and evolocumab directly to the front lines of medical cardiology practice?

Have studies been done looking at PCSK9 inhibitors as monotherapy in post-ACS patients with elevated LDL-C levels?

Have studies been done looking at PCSK9 inhibitors as monotherapy in post-ACS patients with elevated LDL-C levels?

Showing 1 - 12 of 98 results

Previous| 1 | 2 | 3 | 4 | 5 ...9 |Next